We plan to expand our hypothesis that certain metabolites of aldosterone (Aldo), present in kidney during the latent period, play significant role(s) in the regulation and/or expression of the individual renal Na+ and K+ actions of Aldo. The proposed experiments focus on the mechanisms which regulate the key sequences, subcellular sites, and specific enzymes in the metabolic pathways of Aldo in both liver and kidney, which lead to active, inactive, or potentially-active metabolites. Regulation of the key enzymes (5 alpha - and 5 beta-reductases, 3 alpha- and 3 beta-dehydrogenases, cytochrome P-450 hydroxylases, and those leading to carboxylic acids and sulfates) will be studied using (3H)-Aldo and -Ring-A-reduced intermediates in male rats, and compared to (a) females, (b) males fed low or high Na+ diet, and (c) males fed high K+ diet. Sufficient quantities of each of the polar neutral hydroxylated metabolites of Aldo (NMA) will be synthesized in liver and kidney to complete their chemical identification (by high resolution NMR, GC- and LC-Mass Spec.). Also, the further metabolism and activation/inactivation of Ring- A-reduced, NMA, 19-OH-, 19-nor-, carboxylic acid, and sulfate derivatives of Aldo will be studied (in kidney, liver and toad bladder) and the products will be isolated and chemically identified. Each derivative will be tested: (a) acutely (s.c.) and chronically (infusion) in adrenalectomized (ADX) rats for mineralocorticoid (MC) activity, and ability to enhance or inhibit individual Na+ and K+ effects of Aldo; (b) chronically in intact rats for effects and feedback on plasma renin activity and concentration, and plasma Aldo levels; (c) in ADX rats and ADX SHR for effects on blood pressure; (d) in toad bladder for ability to stimulate Na+ and H2O transport or to alter actions of Aldo or vasopressin on these processes; and (e) in rats fed either low Na+ or high K+ diet for possible enhancement of MC activities of Aldo, Ring-A-reduced and other active metabolites. Receptor interactions of these metabolites, their specific location and sites of synthesis in renal tubules, and effects on Na+, K+-ATPase will be assessed. The magnitude of key metabolic pathways in young, pre- and older, hypertensive rats (SHR and Dahl-S) will be studied. These proposed studies will highlight the importance of key metabolic pathways leading to biologically active metabolites, their physiological regulation and specific role in the mechanism of action of Aldo, and the pathogenesis of hypertension.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK021404-08
Application #
3226958
Study Section
Cardiovascular and Pulmonary Research B Study Section (CVB)
Project Start
1979-09-30
Project End
1989-08-31
Budget Start
1988-09-01
Budget End
1989-08-31
Support Year
8
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Miriam Hospital
Department
Type
DUNS #
039318308
City
Providence
State
RI
Country
United States
Zip Code
02906
Morris, D J; Souness, G W; Brem, A S et al. (2000) Interactions of mineralocorticoids and glucocorticoids in epithelial target tissues. Kidney Int 57:1370-3
Morris, D J; Latif, S A; Rokaw, M D et al. (1998) A second enzyme protecting mineralocorticoid receptors from glucocorticoid occupancy. Am J Physiol 274:C1245-52
Latif, S A; Sheff, M F; Ribeiro, C E et al. (1997) Selective inhibition of sheep kidney 11 beta-hydroxysteroid dehydrogenase isoform 2 activity by 5 alpha-reduced (but not 5 beta) derivatives of adrenocorticosteroids. Steroids 62:230-7
Morris, D J; Souness, G W (1996) Endogenous 11 beta-hydroxysteroid dehydrogenase inhibitors and their role in glucocorticoid Na+ retention and hypertension. Endocr Res 22:793-801
Souness, G W; Morris, D J (1996) 11 alpha- and 11 beta-hydroxyprogesterone, potent inhibitors of 11 beta-hydroxysteroid dehydrogenase, possess hypertensinogenic activity in the rat. Hypertension 27:421-5
Souness, G W; Latif, S A; Laurenzo, J L et al. (1995) 11 alpha- and 11 beta-hydroxyprogesterone, potent inhibitors of 11 beta-hydroxysteroid dehydrogenase (isoforms 1 and 2), confer marked mineralocorticoid activity on corticosterone in the ADX rat. Endocrinology 136:1809-12
Morris, D J (1995) The role of steroid metabolism in protective and specificity conferring mechanisms of mineralocorticoid action. Vitam Horm 50:461-85
Souness, G W; Myles, K; Morris, D J (1994) Other physiological considerations of protective mechanisms of mineralocorticoid action. Steroids 59:142-7
Latif, S A; Hartman, L R; Souness, G W et al. (1994) Possible endogenous regulators of steroid inactivating enzymes and glucocorticoid-induced Na+ retention. Steroids 59:352-6
Morris, D J (1993) Liquorice: new insights into mineralocorticoid and glucocorticoid hypertension. R I Med 76:251-4

Showing the most recent 10 out of 24 publications